Previous 10 | Next 10 |
The FDA has granted orphan drug designation to Akari Therapeutics' (NASDAQ: AKTX ) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). More news on: Akari Therapeutics, Plc, Healthcare stocks news, Read more .....
NEW YORK and LONDON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, toda...
Akari Therapeutics (NASDAQ: AKTX ): Q2 GAAP EPS of $0.00 beats by $0.27 . More news on: Akari Therapeutics, Plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
- Positive early safety and efficacy data with nomacopan Phase II clinical study in patients with mild-to-moderate bullous pemphigoid (BP) announced April 2019 Phase I/II clinical study in patients with moderate-to-severe atopic keraconjunctivitis (AKC) announced June 2019 ...
Briggs & Stratton (NYSE: BGG ) -47% . on Q4 earnings & dividend cut. More news on: Briggs & Stratton Corporation, Just Energy Group Inc., Akari Therapeutics, Plc, Stocks on the move, Read more ...
It’s not easy to get approval from the FDA. There are steps to follow, standards to meet. Sometimes, companies fail. But Akari Therapeutics (NASDAQ:AKTX) is not one of them, receiving Fast Track approval from the federal agency this week. On the news, AKTX stock jumped, currently u...
Gainers: Infrastructure and Energy Alternatives (NASDAQ: IEA ) +61% . Novavax (NASDAQ: NVAX ) +40% . Akari Therapeutics (NASDAQ: AKTX ) +31% . Xunlei Limited (NASDAQ: XNET ) +30% . Presidio (NASDAQ: PSDO ) +21% . Purple Innovation (NASDAQ: PRPL ) +22% . InMode (NASDAQ: INMD ) ...
Akari Therapeutics (NASDAQ: AKTX ) +57% as nomacopan Fast Track'd for HSCT-TMA. More news on: Akari Therapeutics, Plc, InMode Ltd., Presidio, Inc., Stocks on the move, Read more ...
Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) is up 62% premarket on robust volume in reaction to the FDA's granting of Fast Track status for Coversin (nomacopan) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA...
Fast Track designation by the U.S. Food and Drug Administration (FDA) facilitates the development and expedites the review of new medicines like nomacopan that treat serious unmet medical needs and in Akari’s case, pediatric patients with HSCT-TMA. The Fast Track designat...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan...
BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights. ...
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potenti...